SCHEMBL5251534

SCHEMBL5251534

Cc1n[nH]c2nc3ccccc3nc12

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP1A2 P05177 3/20 0.46
▸ KDM4E B2RXH2 3/20 0.46
▸ ALDH1A1 P00352 3/20 0.46
▸ CYP2C19 P33261 2/20 0.46
▸ RAB9A P51151 2/20 0.46
▸ CASP7 P55210 2/20 0.46
▸ HSD17B10 Q99714 2/20 0.46
▸ PABPC1 P11940 1/20 0.46
▸ ADORA2A P29274 1/20 0.46
▸ ADORA2B P29275 1/20 0.46
▸ BLM P54132 1/20 0.46
▸ PMP22 Q01453 1/20 0.46
▸ TDP1 Q9NUW8 1/20 0.46
▸ MAPT P10636 3/20 0.43
▸ TP53 P04637 2/20 0.43
▸ NPC1 O15118 1/20 0.43
▸ POLB P06746 1/20 0.43
▸ CASP1 P29466 1/20 0.43
▸ MAPK10 P53779 1/20 0.43
▸ SMN1; SMN2 Q16637 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Quinoxaline1 SCHEMBL29447180 0.76 MAPT (0.52) CYP1A2KDM4EALDH1A1CYP2C19RAB9A
Quinoxaline1 SCHEMBL1394500 0.76 MAPT (0.52) CYP1A2KDM4EALDH1A1CYP2C19RAB9A
SCHEMBL23229339 0.73 DYRK1A (0.36) —
SCHEMBL5247702 0.73 ALDH1A1 (0.46) CYP1A2KDM4EALDH1A1CYP2C19RAB9A
SCHEMBL9006212 0.68 MAOA (0.48) CYP1A2KDM4EALDH1A1HSD17B10CYP3A4
SCHEMBL29364974 0.67 MAPT (0.62) CYP1A2KDM4EALDH1A1HSD17B10TDP1
SCHEMBL103601 0.67 MAPT (0.62) CYP1A2KDM4EALDH1A1HSD17B10TDP1
SCHEMBL5793827 0.67 DYRK1A (0.31) —
SCHEMBL29581806 0.67 MAPT (0.71) CYP1A2KDM4EALDH1A1CYP2C19RAB9A
SCHEMBL2246928 0.67 MAPT (0.71) CYP1A2KDM4EALDH1A1CYP2C19RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1373270-B1 TRICYCLIC QUINOXALINE DERIVATIVES AS A UV FILTER MERCK PATENT GMBH (DE) 2007-06-06 — — EP disclosed
EP-1373270-B1 TRICYCLIC QUINOXALINE DERIVATIVES AS A UV FILTER MERCK PATENT GMBH (DE) 2007-06-06 — — EP disclosed
US-20060222607-A1 Tricyclic quinoxaline and quinoline derivatives as UV filters PFLUCKER FRANK 2006-10-05 — — US disclosed
US-7101537-B2 Tricyclic quinoxaline and quinoline derivatives as a UV filter MERCK PATENTGESELLSCHAFT (DE) 2006-09-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060222607-A1 Tricyclic quinoxaline and quinoline derivatives as UV filters RECQL, CUTA, NQO2 CYP1A2 50/4885KDM4E 1602/4885ALDH1A1 682/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback